Dr. Joseph Lane is Chief of the Metabolic Bone Disease Service at HSS and specializes in fractures, bone tumors, and metabolic bone diseases including osteoporosis and other bone disorders.
Born in New York City and raised in Great Neck, Long Island, Dr. Lane received his undergraduate degree (Magna Cum Laude) from Columbia College and his medical degree from Harvard Medical School. His general surgical internship and residency were performed at Hospital of the University of Pennsylvania. Dr. Lane performed bone collagen research at the NIDR at NIH (USPHS) from 1967-69 in Bethesda, Maryland, under Karl Piez and Edward Miller. He had a collagen research fellowship under Darwin Prochop at the CCRC University of Pennsylvania and a three-year orthopedic residency at the Hospital of the University of Pennsylvania during which time he was awarded the Kappa Delta Award (AAOS) for inhibiting scar formation.
Dr. Lane was the Elsee Butz Assistant Professor (orthopedics) at the Hospital University of Pennsylvania and Children’s Hospital of Philadelphia (1973-75). He was appointed Assistant Professor and Chief of the Metabolic Bone Disease Service at Hospital for Special Surgery/Cornell Medical School in 1975, ultimately attaining full Professorship, Assistant Dean, Director of Clinical Research, and Medical Director of the Metabolic Bone Disease Service and Osteoporosis Prevention (1976-93, 96-present). He was appointed Chief of the Bone Tumor Service (osteogenic sarcoma, Ewing’s sarcoma) at Memorial Sloan Kettering Cancer Center (1976-91) and Senior Attending (1991-93). From 1993-96 he was Professor and Chairman of the Department of Orthopaedic Surgery at UCLA. He is currently the Associate Director of the Orthopaedic Trauma Service at NewYork-Presbyterian Hospital.
Dr. Lane has published extensively on bone biology, tissue injury and repair, trauma, bone and soft tissue sarcomas (including osteogenic sarcoma and Ewing’s sarcoma), limb preservation, functional amputations, limb regeneration, and metabolic bone diseases (osteoporosis, Paget’s disease, rickets, osteomalacia, fibrous dysplasia).
He has served on numerous committees for the AAOS, including the Board of Directors and Chairman of COMSS, the Chairman Oversight Panel on Women’s Health Issues. He was President of the Orthopaedic Research Society, Musculoskeletal Tumor Society, Chairman of NIH Orthopaedic Study Section, OREF grants review board, ABOS Question Writing Task Force. He is a member of the AAOS, AOA, ABJS, ASBMR, ORS, MSTS, and OTA. He has earned NIH career and R01 grants, OREF grants, and foundation awards. He has been a visiting professor at educational institutes and is on the editorial board of several peer journals.
Malignant and benign bone tumors (osteoglenic, Ewing’s, and soft-tissue sarcomas)
Fractures, non-unions, and delayed healing
Metabolic bone disease (osteoporosis, Paget’s disease, rickets, osteomalacia, fibrous dysplasia, melorheostosis)
Geriatric vertebral compression fractures
Geriatric hip fractures
Please call our office if you have questions regarding your insurance coverage. If you have out of network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Attending Orthopedic Surgeon, Hospital for Special Surgery
Chief, Metabolic Bone Disease Service, Hospital for Special Surgery
Assistant Dean, Hospital for Special Surgery, Weill Cornell Medical College and affiliated hospitals, NYC
Professor of Orthopedic Surgery, Weill Cornell Medical College
Attending Orthopedic Surgeon, NewYork-Presbyterian Hospital
Adjunct Professor, Department of Orthopedic Surgery, Columbia University, College of Physicians & Surgeons
Chief, Metabolic Bone Disease Service
National Board of Medical Examiners
American Board of Orthopaedic Surgeons, September 1974
Board Recertification—American Board of Orthopaedic Surgeons, July 1998
HSS Lifetime Achievement Award, 2011
Castle Connolly America's Top Doctors, 2003-2018
Castle Connolly Regional Top Doctor, 2012-2018
Castle Connolly Top Doctors in New York Metro Area, 2002-2018
FDA Orthopaedic Panel, 1999-2018
New York State Osteoporosis and Education Program (NYSOPEP), 1999
NIH Tissue Engineering Grant Review Panel, 1998-2018
NIH Sickle Cell Hip Program - Oversight Committee, 1998-2018
Castle Connolly America's Top Doctors for Cancer, 2005-2014
New York Magazine Top Doctors, 2002-2009
New York Magazine Top Minimally Invasive Doctors, 2002
NIH Consensus on Total Hip Replacement - Panelist, 1994
MD, Harvard Medical School, 1965
Hospital of the University of Pennsylvania, Department of General Surgery, Pennsylvania, 1966-67
Hospital of the University of Pennsylvania, Department of Orthopaedic Surgery, Pennsylvania, 1972-73
National Institute of Arthritis and Metabolic Disease, NIH (USPHS), Research Associate
General Clinical Research Center, Collagen Metabolism (Darwin Prochop), Research Associate
For more publications, please see the PubMed listing.
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
Below are the healthcare industry relationships reported by Dr. Lane as of February 03, 2022.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
Patients should feel free to ask their HSS physicians questions about these relationships.